Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Jiving I have posted this before but it deals with a pre-patent protection
https://pharmaphorum.com/news/biogen-protects-tecfidera-1-25bn-deal-forward/
Older confirmed NFX had commenced discussions with AZ after the patent submission in November, no other marketing, so is there some intent, so how long to then notify the market or can AZ take as much time as they want
Jiving yes past performance not ideal however NXP001 was not a blockbuster and development was for a previously untried area. I should imagine independent valuations will be sought and ignored, the difficulty has become with the enormity of the recent approvals. Current sales are $2.7bn with estimates of $9.7bn by 2028, so value is a challenge, this was originally $1bn blockbuster when NFX started. There is no doubt there is significant value to protect market share, I don’t envy their task, but there are industry specialists who value these assets wish one would just state what they think the drug is worth.
This is interesting as it gives an insight to the threat of patent expiry as well as commenting on Lynparza
https://pharmaphorum.com/news/az-says-recovery-to-continue-to-despite-patent-expiry-and-brexit-headwinds/
One expires this year and it looks like the balance expire in 2 years time
https://www.drugpatentwatch.com/p/tradename/LYNPARZA
Merck outperforming re Nasdaq research
https://www.nasdaq.com/articles/merck-mrk-outperforms-industry-this-year-so-far%3A-heres-why?amp
Filter it appears gone are the days the market anticipate s value but as you know over the last 2 to 3 years there has been a constant supply of stock to the market from big holders and when the market knows that they do not have to worry about supply.
I agree 002 is first as it is in play however we are in month 20 of the 004 patent application. This has to be a real worry for AZ/Merck as on average it takes 22 months for patent approval, when that happens how many pharmas would pay to get access to a world top ten drug? The longer they wait the greater the risk that a US pharma will buy the licence or the company.
If the forecast is correct Lynparza will be the 6th ranked drug in the world, that will be worth a few bob
https://www.nature.com/articles/d41573-022-00047-9
This is why I believe Lynparza is massive annual sales will far exceed Tranilast and it will become one of the world leaders
https://www.marketwatch.com/amp/story/svb-leerink-astrazenecas-lynparza-could-bring-in-97-billion-in-sales-by-2028-2022-03-14
Merck to present extended pipeline for 6 drugs including Lynparza at the ASCO meeting in June
https://stockhouse.com/news/press-releases/2022/05/10/merck-to-present-data-at-2022-asco-annual-meeting-highlighting-promising